Want to see CELC full AI Analyst Report?
CELC Stock Chart & Stats
$82.62
$0.23(0.28%)
At close: 4:00 PM EDT
$82.62
$0.23(0.28%)
Day’s Range― - ―
52-Week Range$44.42 - $151.02
Previous CloseN/A
Volume428.06K
Average Volume (3M)1.57M
Market Cap
$4.50B
Enterprise Value$5.74K
Total Cash (Recent Filing)$754.04M
Total Debt (Recent Filing)$754.38M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 18, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.29
Shares Outstanding48,931,908
10 Day Avg. Volume2,363,349
30 Day Avg. Volume1,572,523
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)52.11
Price to Sales (P/S)0.00
P/FCF Ratio-34.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.12
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$160.89Price Target Upside94.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.22
Revenue Forecast (FY)$39.92M
Bulls Say, Bears Say
Bulls Say
Regulatory And Guideline AdoptionFDA approval creates a commercial foundation, while NCCN Category 1 preferred status can support physician adoption and payer discussions. Together, these regulatory and guideline milestones strengthen gedatolisib’s position in the second-line breast cancer treatment pathway.
Phase 3 Efficacy And TolerabilitySuperior progression-free survival and substantially lower adverse-event discontinuation provide a durable clinical differentiation versus the comparator. These results may improve treatment persistence, physician confidence and the drug’s ability to compete in targeted oncology.
Commercial Launch Funding And ReadinessA multiyear cash runway and established commercial infrastructure give Celcuity resources to launch Revtopik, support market access and advance additional programs. This reduces immediate financing dependence while the company converts regulatory progress into recurring product revenue.
Bears Say
Pre-revenue Business ModelThe absence of commercial revenue leaves Celcuity dependent on financing and successful execution of the Revtopik launch. Until recurring sales develop, widening losses make operating performance highly sensitive to development costs, launch timing and market adoption.
High And Increasing Cash BurnPersistently negative cash generation indicates that commercialization and clinical programs currently consume substantial funding. The higher quarterly burn, driven partly by launch investment, could shorten financial flexibility if revenue ramp-up or reimbursement progress is slower than planned.
Leverage, Dilution And Supply Execution RiskNegative equity and elevated debt increase refinancing and dilution risk for a pre-revenue company, even after the term-loan refinancing. Dependence on FDA clearance for a secondary manufacturing site also leaves launch supply vulnerable to regulatory delay.
Celcuity News
CELC FAQ
What was Celcuity Inc.’s price range in the past 12 months?
Celcuity Inc. lowest stock price was $44.42 and its highest was $151.02 in the past 12 months.
What is Celcuity Inc.’s market cap?
Celcuity Inc.’s market cap is $4.50B.
When is Celcuity Inc.’s upcoming earnings report date?
Celcuity Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 92 days.
How were Celcuity Inc.’s earnings last quarter?
Celcuity Inc. released its earnings results on Aug 13, 2026. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$0.275.
Is Celcuity Inc. overvalued?
According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued.
Does Celcuity Inc. pay dividends?
Celcuity Inc. does not currently pay dividends.
What is Celcuity Inc.’s EPS estimate?
Celcuity Inc.’s EPS estimate is -1.41.
How many shares outstanding does Celcuity Inc. have?
Celcuity Inc. has 48,931,908 shares outstanding.
What happened to Celcuity Inc.’s price movement after its last earnings report?
Celcuity Inc. reported an EPS of -$1.44 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went up 6.236%.
Which hedge fund is a major shareholder of Celcuity Inc.?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$160.89 (94.73% Upside)
$160.89 (94.73% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 93%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $317.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
488.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
351.12%
Trailing 12-Months
Company Description
Celcuity Inc.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
CELC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: regulatory approval (FDA), rapid NCCN Category 1 endorsement, robust phase 3 efficacy (large PFS gains and lower discontinuation vs comparator), commercial launch readiness, a sizeable addressable market (> $6B annual TAM) and a fortified balance sheet with a cash runway into 2029. Offsetting risks include materially higher operating losses and SG&A tied to launch investments, increased near-term cash burn, conditional reliance on FDA review for a secondary manufacturing site (supply risk), and limited real-time utilization visibility for an IV therapy. Overall, the operational and clinical wins materially outweigh the financial and execution risks described.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$160.89
▲(94.73% Upside)
Technical Analysis
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―
Ownership Overview
18.33% Insiders
12.24% Mutual Funds
11.92% Other Institutional Investors
46.28% Public Companies and
Individual Investors